Business
Press Release Dec 11 2025
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%".
About this update from Alembic Pharmaceuticals Limited
[{"type":"text","content":" Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled \"Alembic Pharmaceuticals Limited receives USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%\". View Attachment","length":418,"tagName":"div"}]